Five biopsy specimens from the proximal part of the tumor reliably determine HER2 protein expression status in gastric cancer

Naoyuki Tominaga*, Takuji Gotoda, Megumi Hara, Matthew D. Hale, Takayoshi Tsuchiya, Jun Matsubayashi, Shin Kono, Chika Kusano, Takao Itoi, Kazuma Fujimoto, Fuminori Moriyasu, Heike I. Grabsch*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

National guidelines recommend trastuzumab for treatment of patients with metastatic HER2-positive gastric cancer (GC). There is currently no guideline indicating the number of biopsy specimens and the location from which they should be obtained to reliably determine the human epidermal growth factor receptor 2 (HER2) status in GC. The aim of this pilot study was (a) to quantify HER2-positive tumor cells in different tumor regions to assess the spatial heterogeneity of HER2 expression and (b) to establish the required number of biopsy specimens and the location from which they should be obtained within the tumor to achieve concordance between HER2 expression status in the biopsy specimens and the resection specimen. HER2 expression was quantified in six different regions of 24 HER2-positive GC and in six virtual biopsy specimens from different luminal regions. Intratumoral regional heterogeneity and concordance between HER2 status in the biopsy specimens and the resection specimen were analyzed. HER2-positive cells were more frequent in the luminal tumor surface compared with deeper layers (p <0.001). GCs with differentiated histological features were more commonly HER2 positive (p <0.001). Assessment of HER2 expression status in five biopsy specimens was sufficient to achieve 100 % concordance between the biopsy specimens and the resection specimen. This is the first study to suggest preferential HER2 positivity at the luminal surface in GC and to establish a minimum number of biopsy specimens needed to obtain a biopsy HER2 result which is identical to that from the whole tumor. Our study suggests that HER2 testing in five tumor-containing endoscopic biopsy specimens from the proximal (oral) part of the tumor is advisable. The results from this pilot study require validation in a prospective study.
Original languageEnglish
Pages (from-to)553-560
JournalGastric Cancer
Volume19
Issue number2
DOIs
Publication statusPublished - Apr 2016

Keywords

  • HER2 expression
  • Gastric cancer
  • Virtual biopsy

Fingerprint

Dive into the research topics of 'Five biopsy specimens from the proximal part of the tumor reliably determine HER2 protein expression status in gastric cancer'. Together they form a unique fingerprint.

Cite this